GYRE THERAPEUTICS INC(NASDAQ:GYRE) stock Fundamental Analysis

Fundamental Rating

Overall GYRE gets a fundamental rating of 5 out of 10. We evaluated GYRE against 571 industry peers in the Biotechnology industry. While GYRE has a great health rating, there are worries on its profitability. GYRE is not valued too expensively and it also shows a decent growth rate.

Quickly go to:

1. Profitability

1.1 Basic Checks

In the past year GYRE has reported negative net income.

GYRE had a positive operating cash flow in the past year.

In the past 5 years GYRE always reported negative net income.

In the past 5 years GYRE reported 4 times negative operating cash flow.

1.2 Ratios

GYRE's Return On Assets of -61.45% is in line compared to the rest of the industry. GYRE outperforms 41.00% of its industry peers.

With a Return On Equity value of -121.81%, GYRE is not doing good in the industry: 60.07% of the companies in the same industry are doing better.

The Return On Invested Capital of GYRE (31.09%) is better than 99.82% of its industry peers.

		Industry Rank	Sector Rank
ROA	-61.45%
ROE	-121.81%
ROIC	31.09%

ROA(3y)-88.87%

ROA(5y)-76.38%

ROE(3y)-158.6%

ROE(5y)-126.1%

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

GYRE's Operating Margin of 22.74% is amongst the best of the industry. GYRE outperforms 96.61% of its industry peers.

GYRE's Gross Margin of 96.16% is amongst the best of the industry. GYRE outperforms 96.79% of its industry peers.

In the last couple of years the Gross Margin of GYRE has grown nicely.

		Industry Rank	Sector Rank
OM	22.74%
PM (TTM)	N/A
GM	96.16%

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y19.45%

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

GYRE has a Return on Invested Capital (ROIC), which is well above the Cost of Capital (WACC), which means it is creating value.

Compared to 1 year ago, GYRE has more shares outstanding

The number of shares outstanding for GYRE has been increased compared to 5 years ago.

GYRE has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.

2.2 Solvency

GYRE has an Altman-Z score of 11.81. This indicates that GYRE is financially healthy and has little risk of bankruptcy at the moment.

The Altman-Z score of GYRE (11.81) is better than 88.59% of its industry peers.

GYRE has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	0
Altman-Z	11.81

ROIC/WACC3.3

WACC9.41%

2.3 Liquidity

GYRE has a Current Ratio of 3.72. This indicates that GYRE is financially healthy and has no problem in meeting its short term obligations.

GYRE has a Current ratio (3.72) which is in line with its industry peers.

A Quick Ratio of 3.29 indicates that GYRE has no problem at all paying its short term obligations.

Looking at the Quick ratio, with a value of 3.29, GYRE is in line with its industry, outperforming 40.46% of the companies in the same industry.

		Industry Rank	Sector Rank
Current Ratio	3.72
Quick Ratio	3.29

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

GYRE shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 98.89%, which is quite impressive.

The Revenue has grown by 14260.76% in the past year. This is a very strong growth!

The Revenue has been growing by 547.08% on average over the past years. This is a very strong growth!

EPS 1Y (TTM)98.89%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%102.12%

Revenue 1Y (TTM)14260.76%

Revenue growth 3Y75.61%

Revenue growth 5Y547.08%

Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 33.78% on average over the next years. This is a very strong growth

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

EPS Next Y118.65%

EPS Next 2Y50.41%

EPS Next 3Y33.78%

EPS Next 5YN/A

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for GYRE. In the last year negative earnings were reported.

The Price/Forward Earnings ratio is 17.82, which indicates a rather expensive current valuation of GYRE.

Compared to the rest of the industry, the Price/Forward Earnings ratio of GYRE indicates a rather cheap valuation: GYRE is cheaper than 95.01% of the companies listed in the same industry.

The average S&P500 Price/Forward Earnings ratio is at 22.65. GYRE is valued slightly cheaper when compared to this.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	17.82

4.2 Price Multiples

Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of GYRE indicates a rather cheap valuation: GYRE is cheaper than 95.54% of the companies listed in the same industry.

GYRE's Price/Free Cash Flow ratio is rather cheap when compared to the industry. GYRE is cheaper than 94.83% of the companies in the same industry.

		Industry Rank	Sector Rank
P/FCF	41.24
EV/EBITDA	20.85

4.3 Compensation for Growth

The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.

A more expensive valuation may be justified as GYRE's earnings are expected to grow with 33.78% in the coming years.

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y50.41%

EPS Next 3Y33.78%

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

GYRE does not give a dividend.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

GYRE THERAPEUTICS INC

NASDAQ:GYRE (2/25/2025, 8:00:01 PM)

11.44

+0.89 (+8.44%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryBiotechnology

Earnings (Last)10-24 2024-10-24/amc

Earnings (Next)03-24 2025-03-24/amc

Inst Owners1.96%

Inst Owner Change-95.28%

Ins Owners6.18%

Ins Owner Change0%

Market Cap1.07B

Analysts82.86

Price TargetN/A

Short Float %5.26%

Short Ratio11.5

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Yearly Dividend19.57

Dividend Growth(5Y)N/A

DP16.63%

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)N/A

Avg EPS beat(2)N/A

Min EPS beat(2)N/A

Max EPS beat(2)N/A

EPS beat(4)N/A

Avg EPS beat(4)N/A

Min EPS beat(4)N/A

Max EPS beat(4)N/A

EPS beat(8)N/A

Avg EPS beat(8)N/A

EPS beat(12)N/A

Avg EPS beat(12)N/A

EPS beat(16)N/A

Avg EPS beat(16)N/A

Revenue beat(2)N/A

Avg Revenue beat(2)N/A

Min Revenue beat(2)N/A

Max Revenue beat(2)N/A

Revenue beat(4)N/A

Avg Revenue beat(4)N/A

Min Revenue beat(4)N/A

Max Revenue beat(4)N/A

Revenue beat(8)N/A

Avg Revenue beat(8)N/A

Revenue beat(12)N/A

Avg Revenue beat(12)N/A

Revenue beat(16)N/A

Avg Revenue beat(16)N/A

PT rev (1m)N/A

PT rev (3m)N/A

EPS NQ rev (1m)N/A

EPS NQ rev (3m)N/A

EPS NY rev (1m)0%

EPS NY rev (3m)0%

Revenue NQ rev (1m)N/A

Revenue NQ rev (3m)N/A

Revenue NY rev (1m)0%

Revenue NY rev (3m)0%

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	17.82
P/S	5.59
P/FCF	41.24
P/OCF	28.99
P/B	16.93
P/tB	16.98
EV/EBITDA	20.85

EPS(TTM)-0.23

EYN/A

EPS(NY)0.64

Fwd EY5.61%

FCF(TTM)0.28

FCFY2.42%

OCF(TTM)0.39

OCFY3.45%

SpS2.05

BVpS0.68

TBVpS0.67

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-61.45%
ROE	-121.81%
ROCE	39.36%
ROIC	31.09%
ROICexc	40.23%
ROICexgc	40.31%
OM	22.74%
PM (TTM)	N/A
GM	96.16%
FCFM	13.56%

ROA(3y)-88.87%

ROA(5y)-76.38%

ROE(3y)-158.6%

ROE(5y)-126.1%

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexcg growth 3YN/A

ROICexcg growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y19.45%

GM growth 5YN/A

F-Score6

Asset Turnover1.53

Health

		Industry Rank	Sector Rank
Debt/Equity	0
Debt/FCF	0
Debt/EBITDA	0
Cap/Depr	N/A
Cap/Sales	N/A
Interest Coverage	250
Cash Conversion	80.83%
Profit Quality	N/A
Current Ratio	3.72
Quick Ratio	3.29
Altman-Z	11.81

F-Score6

WACC9.41%

ROIC/WACC3.3

Cap/Depr(3y)355.37%

Cap/Depr(5y)293.22%

Cap/Sales(3y)6.16%

Cap/Sales(5y)N/A

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)98.89%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%102.12%

EPS Next Y118.65%

EPS Next 2Y50.41%

EPS Next 3Y33.78%

EPS Next 5YN/A

Revenue 1Y (TTM)14260.76%

Revenue growth 3Y75.61%

Revenue growth 5Y547.08%

Sales Q2Q%N/A

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

EBIT growth 1Y421.29%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next YearN/A

EBIT Next 3YN/A

EBIT Next 5YN/A

FCF growth 1Y152.62%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y174.87%

OCF growth 3YN/A

OCF growth 5YN/A

GYRE THERAPEUTICS INC (GYRE) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens